Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Biosimilarity of GP40221 vs Ozempic in Healthy Volunteers
NCT06497049Phase 1Completed
- Sponsor
- Geropharm
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Geropharm. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration at 288 hours and Maximum plasma concentration at 288 hours. Started Jun 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06497049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497049.